Hans Edgar Bishop has sold JUNO and made no open-market buys since Mar 2016

Hans Edgar Bishop is a biotechnology executive and corporate insider best known as the founder, president, and chief executive officer of Juno Therapeutics, Inc., where he led the company from its inception in July 2013 through its acquisition by Celgene Corporation in March 2018.( During his tenure at Juno, a cellular immunotherapy company focused on cancer, he helped grow the business into a leading player in CAR‑T therapies and oversaw its multibillion‑dollar sale to Celgene.( Regulatory filings identify him as CEO & President of Juno Therapeutics, Inc. (JUNO) and a significant shareholder, with substantial equity holdings and insider trading activity reported around the time of the Celgene transaction.(

Bishop has more than 30 years of experience in the biotechnology and pharmaceutical industries, holding senior roles that include Executive Vice President and Chief Operating Officer at Dendreon Corporation, President of Specialty Medicine at Bayer Healthcare, and Senior Vice President of Global Commercial Operations at Chiron Corporation.( After Juno, he served as Chief Executive Officer of GRAIL, Inc., a cancer‑detection company later acquired by Illumina, and went on to become President, Founder, and Board Co‑Chair of Altos Labs, Inc., as well as Chairman of the Board of Sana Biotechnology, Inc.( He has also served on the boards of Agilent Technologies, Lyell Immunopharma, Celgene, JW Therapeutics, and other life sciences companies.( Bishop holds a B.A. in Chemistry from Brunel University in London, providing the scientific foundation for his long career in oncology and biotechnology leadership.(

Written by Perplexity from public sources.